Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science
Niagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Business to LGC in All-Cash Transaction
ChromaDex Evolves Into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ With Precision Science
ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025
ChromaDex to Present at the 37th Annual Roth Conference
ChromaDex Capitalizes On Longevity Boom But Valuation Remains High
ChromaDex Corporation (CDXC) Q4 2024 Earnings Call Transcript
ChromaDex (CDXC) Q4 Earnings and Revenues Surpass Estimates
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results
Pick These 4 Stocks With Solid Net Profit Margin to Boost Return
ChromaDex to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow
ChromaDex (CDXC) is on the Move, Here's Why the Trend Could be Sustainable
ChromaDex Named to the Inc. 2024 Best in Business List in the Health Products Category
ChromaDex Corporation (CDXC) Hits Fresh High: Is There Still Room to Run?
Recent Price Trend in ChromaDex (CDXC) is Your Friend, Here's Why
ChromaDex's Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology's Inaugural Longevity Supplement
What Makes ChromaDex (CDXC) a Strong Momentum Stock: Buy Now?
5 Stocks With Recent Price Strength to Tap Wall Street Rally
ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide
ChromaDex Corporation (CDXC) Hit a 52 Week High, Can the Run Continue?
ChromaDex (CDXC) Is a Great Choice for 'Trend' Investors, Here's Why
ChromaDex Corporation (CDXC) Q3 2024 Earnings Call Transcript
ChromaDex (CDXC) Beats Q3 Earnings and Revenue Estimates
ChromaDex Gears Up to Report Q3 Earnings: Here's What to Expect
ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
ChromaDex to Participate in the 17th Annual LD Micro Main Event
Are Medical Stocks Lagging ChromaDex (CDXC) This Year?
Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN)
ChromaDex to Participate in a Fireside Chat at the Lytham Partners Fall 2024 Investor Conference
Is ChromaDex (CDXC) Stock Outpacing Its Medical Peers This Year?
ChromaDex Appoints Ozan Pamir as Chief Financial Officer
ChromaDex Announces Expansion of Pharmaceutical-Grade Niagen® IV and Injection Offerings to Additional Leading Wellness Clinics
ChromaDex Celebrates 25 Years of Innovation and Pioneering NAD+ Research for Healthy Aging Solutions
ChromaDex to Participate in Renmark's Virtual Non-Deal Roadshow Series On Thursday, August 29, 2024
ChromaDex (CDXC) Reports Break-Even Earnings for Q2
ChromaDex Appoints Carlos Lopez as Senior Vice President, General Counsel
ChromaDex Announces Pharmaceutical-Grade Intravenous and Injectable Niagen® Will Debut at Leading Wellness Clinics in August
ChromaDex: Looking To Take The Big Step Into Pharma
Milestone Phase II Clinical Study Demonstrates Niagen®, Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD)
ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC)
ChromaDex (CDXC) Up as Ataxia Candidate Gets Orphan Drug Tag
ChromaDex Receives Exclusive U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric (RPD) Disease Designation for Nicotinamide Riboside Chloride (NRC) for the Treatment of Ataxia Telangiectasia (AT)
ChromaDex to Participate in Renmark's Virtual Non-Deal Roadshow on Tuesday, June 11, 2024
ChromaDex to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
ChromaDex's Niagen® Wins Prestigious NutraIngredients EU Healthy Ageing Ingredient of the Year Award
ChromaDex Corporation (CDXC) Q1 2024 Earnings Call Transcript
ChromaDex's NIAGEN® (Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar® Cellular Nutrition Cellular Energy Supplement
ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe®